Key Highlights
- Enanta Pharmaceuticals (NASDAQ:ENTA) reported fiscal fourth-quarter Revenue of USD 12.9 million, down from USD 15.1 million, and a net loss of USD 23.7 million, or USD 0.81 per diluted share, for the quarter ended September 30, 2026.
- For fiscal 2026, revenue was USD 63.0 million against USD 65.3 million, and the net loss narrowed to USD 68.2 million, or USD 2.35 per share, from USD 81.9 million, or USD 3.84 per share.
- Cash, cash equivalents and marketable securities totalled USD 194.5 million at September 30, 2026, and the company expects that, with retained royalties, to fund operations into fiscal 2029.
- A European Patent court found Enanta's patent against Pfizer's Paxlovid invalid in October, and the company cut its workforce by about one-third while announcing CEO Jay Luly's retirement by February 1, 2027.
Royalty Decline and a Wider Quarterly Loss
Enanta Pharmaceuticals (NASDAQ:ENTA) published fiscal fourth-quarter and full-year results on November 16, 2026. The Watertown, Massachusetts, company is a clinical-stage biotechnology firm developing small molecule drugs for viral infections and immunological diseases. Its only revenue is Royalty income from AbbVie's hepatitis C regimen MAVYRET, which fell to USD 12.9 million in the quarter from USD 15.1 million as AbbVie's sales declined. Of that royalty stream, 54.5% is paid to OMERS under a 2023 royalty sale treated as debt, so interest expense rose to USD 3.5 million in the quarter from USD 2.4 million. The quarterly net loss widened to USD 23.7 million from USD 18.7 million.
Lower Spending Narrows the Annual Loss
Research and development spending was USD 26.1 million in the quarter, up from USD 23.8 million on higher clinical costs for the RESOLVE and LOTUS RSV trials, but fell to USD 88.5 million for the year from USD 106.7 million because of trial timing. General and administrative expense dropped to USD 36.8 million for the year from USD 43.9 million, reflecting lower stock-based compensation and reduced legal costs on the Pfizer case. Interest and Investment income fell to USD 8.2 million from USD 9.4 million on lower rates. In September the company reduced its workforce by approximately one-third after a strategic review, aiming to extend financial flexibility.
Pipeline Milestones, Patent Setback and Leadership Change
Enrollment is complete in LOTUS, a Phase 2b trial of zelicapavir in children with RSV, with topline data expected in the first quarter of 2027, and dosing has begun in RESOLVE, a Phase 2b/3 adult trial with Phase 2b data expected in 2027. Phase 1 data for the KIT inhibitor EDP-978 are now expected in the first quarter of 2027, the EDP-903 STAT6 inhibitor IND moved to the second quarter of 2027 on a Manufacturing delay, and an IND for EPS-5336 is targeted for the fourth quarter of 2027. Enanta Pharmaceuticals (NASDAQ:ENTA) lost its European Unified Patent Court case against Pfizer in October, and a European Patent Office hearing is set for April 2027. CEO Jay Luly, aged 70, will retire by February 1, 2027, and Tara Kieffer was named Chief Operating Officer.
Where Things Stand
The company's USD 194.5 million of cash and marketable securities, plus its retained share of royalties, is projected to fund operations into fiscal 2029, which gives Enanta Pharmaceuticals (NASDAQ:ENTA) roughly two years of runway after the one-third staff reduction. That outlook depends on AbbVie's declining MAVYRET sales, which already trimmed fiscal 2026 revenue to USD 63.0 million. Key markers ahead are LOTUS and EDP-978 data in the first quarter of 2027, the April 2027 patent hearing, the search for a new CEO, and fiscal first-quarter results scheduled for February 8, 2027.






Please wait processing your request...